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ABSTRACT
Introduction: Multiple sclerosis (MS) is an
autoimmune disorder with large annual costs.
This study evaluated utilization and costs for
the management of MS relapses with H.P.
Acthar Gel (repository corticotropin
injection; Acthar; Mallinckrodt) compared to
receipt of plasmapheresis (PMP) or intravenous
immunoglobulin (IVIG) among patients with
MS who experienced multiple relapses.
Methods: We identified patients with MS
diagnoses who had relapses treated with
intravenous methylprednisolone (IVMP), the
first-line treatment for MS relapse. Patients
who were treated for the subsequent relapses
were eligible for the study. We analyzed 12- and
24-month healthcare utilization and costs
among patients who received Acthar
prescriptions compared to patients who were
treated with PMP/IVIG using generalized linear
and logistic regression models to calculate
unadjusted and adjusted means and 95%
confidence intervals.
Results: For the 12-month analysis, a total of
213 patients received Acthar prescriptions and
226 were treated with PMP or IVIG. Patients
who received Acthar prescriptions were similar
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
AAD4F06050B69811.
Electronic supplementary material The online
version of this article (doi:10.1007/s12325-016-0363-0)
contains supplementary material, which is available to
authorized users.
L. S. Gold (&)  K. Suh  R. N. Hansen
Department of Pharmacy, Pharmaceutical
Outcomes Research and Policy Program, University
of Washington, Seattle, WA, USA
e-mail: goldl@uw.edu
L. S. Gold
Department of Radiology, Pharmaceutical
Outcomes Research and Policy Program, University
of Washington, Seattle, WA, USA
P. B. Schepman
Regional Outcomes, Sanofi U.S., Bridgewater, NJ,
USA
K. Damal
Santen Incorporated, Emeryville, CA, USA
R. N. Hansen
Department of Health Services, Pharmaceutical
Outcomes Research and Policy Program, University
of Washington, Seattle, WA, USA
Adv Ther (2016) 33:1279–1292
DOI 10.1007/s12325-016-0363-0
to those who received other treatments in terms
of most demographic variables. Acthar
recipients had fewer hospitalizations (0.2 vs.
0.4; P = 0.01) and received fewer outpatient
services (29 vs. 43; P\0.0001) but received
more prescription medications (36 vs. 30;
P\0.0001) compared to recipients of PMP/
IVIG. Patients who received Acthar
prescriptions had lower inpatient and
outpatient costs ($15,000 lower; P = 0.001;
and $54,000 lower; P\0.0001, respectively)
but similar total costs. Similar results were
seen in the cohort with 24 months of outcome
data.
Conclusion: Acthar may be a useful treatment
option compared to PMP/IVIG for patients with
MS experiencing multiple relapses.
Funding: This study was funded by a grant to
the University of Washington from
Mallinckrodt Pharmaceuticals.
Keywords: Costs; H.P. Acthar gel (repository
corticotropin injection); Healthcare resource
utilization; Intravenous immunoglobulin;
Multiple sclerosis; Neurology; Plasmapheresis
INTRODUCTION
Multiple sclerosis (MS) is an autoimmune
disorder in which cells of the brain and spinal
cord are damaged, causing a wide range of
neurological symptoms. The most common
symptoms of MS exacerbations include
paresthesia, motor symptoms, such as muscle
cramping or spasticity, spinal cord symptoms,
such as bladder, bowel, or sexual dysfunction,
and fatigue [1]. As of 2013, more than
2.3 million people worldwide had been
diagnosed with MS [2]. On average, annual
direct healthcare costs for patients with MS
have been shown to be about $24,000 higher
compared to the non-MS population [3]. Along
with disease-modifying therapies (DMTs),
which are designed to reduce inflammation
and the risk of subsequent relapses [4, 5], one
of the major drivers of the increased costs in the
MS population is expenses related to treating
MS exacerbations (relapses) [3]. Medicare data
showed that direct costs in patients who
experienced relapses were around $17,000 per
year, while the costs during remission were
about $7300 per year and costs during periods
of stabilization were around $4000 per year [3].
In addition, the expense of treating relapses
increases with severity [6]. Compared to a
cohort of patients with MS who did not
experience any relapses, those who
experienced low/moderate severity relapses
and high severity relapses had $8269 and
$24,180 higher annual incremental direct
costs, respectively [6]. Furthermore, MS
diagnoses and relapses are associated with
significantly reduced health-related quality of
life [7, 8], with patients with MS having about
ten fewer quality-adjusted life years (QALYs)
compared to patients without MS [9].
MS relapses are usually treated with short
courses of high-dose corticosteroids, including
intravenous methylprednisolone (IVMP) or
high-dose oral prednisone (Deltasone; Pfizer).
However, around 20% of patients with MS who
initiate treatment with high-dose
corticosteroids change to other therapies
within several months, likely due to poor
response [10, 11] or patient preferences [12].
Alternative therapies include intravenous
immunoglobulin (IVIG), which reduces or
prevents activation of inflammatory cells and
alters antibody responses [13], plasmapheresis
(PMP), which may remove circulating
antibodies from blood that cause MS
symptoms [14], and H.P. Acthar Gel
(repository corticotropin injection; Acthar;
1280 Adv Ther (2016) 33:1279–1292
Mallinckrodt), which is thought to have
anti-inflammatory properties and works
through multiple mechanisms that include
indirectly increasing corticosteroid production
[15]. Because few studies have focused on
patients who received therapies besides IVMP,
the purpose of this paper was to describe and
generate hypotheses regarding health
utilization, outcomes, and costs resulting from
the management of MS relapses with Acthar
compared to PMP or IVIG among patients with
MS who experienced multiple relapses.
METHODS
Study Population and Data Source
Weused theTruvenHealthAnalyticsMarketScan
Commercial Claims and Encounters Databases to
identify a population of patients with MS. These
databases contained inpatient, outpatient,
pharmacy claims, and insurance coverage data
for patients covered by commercial insurance
plans across the US. The inpatient and outpatient
claimsdatabases includedprocedure andvisit level
details from medical claims, such as the
International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM)
diagnosis and procedure codes, Current
Procedural Terminology (CPT) codes, dates of
service, and variables describing financial
expenditures. The pharmacy claims database
provided details, including National Drug Codes
(NDC), dates dispensed, quantity anddays’ supply,
and payments. Separate eligibility and
demographics file provided additional
information about subjects, such as age, gender,
insurance plan type, geographic location, and
enrollment status by month.
Because we were interested in evaluating
treatments for MS relapses, we limited our study
to patients in the database who experienced at
least two MS exacerbations between July 1, 2007
to December 31, 2012 for the 12-month analyses
or through December 31, 2011 for the 24-month
analyses. Patients in both the 12- and 24-month
analyses were followed for outcomes until
December 31, 2013. We initially identified
eligible patients with MS diagnoses (ICD-9-CM
code 340.X) who had relapses that were treated
with IVMP, the first-line treatment forMS relapse.
Patients who were treated for the subsequent
relapseswere eligible for the study. The indexdate
was the calendar date in which we observed a
subsequent treated relapse at least 30 days after
the initial relapse with the primary ICD-9-CM
diagnosis code forMSalongwithaclaimforoneof
thenon-IVMPrelapse treatments:Acthar, IVIG,or
PMP (Table 1). We excluded patients who were
not enrolled in their health plans continuously
for 6 monthsprior toand for12 (for the12-month
analyses) or 24 (for the 24-month analyses)
months after the index dates.
Statistical Analysis
We examined associations between receipt of
prescriptions for Acthar versus treatment with
PMP/IVIG and 1) 12-month cost and utilization
outcomes and 2) 24-month cost and utilization
outcomes. We initially intended to examine
only 24-month costs and utilization but
examined 12-month outcomes after
discovering that relatively few patients met
our exclusion criteria for 24-month outcomes.
By definition, all the subjects in the 24-month
analyses were also included in the 12-month
analyses. We combined patients who received
PMP with patients who received IVIG because of
small numbers in each individual treatment
group and because these are the next line of
therapies used after corticosteroids [16, 17].
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Patients who received Acthar prescriptions
more than 30 days after their subsequent
exacerbation (index date) were excluded from
these analyses, but patients in the Acthar group
may have received other treatments (IVMP,
IVIG, or PMP) in addition to their Acthar
prescriptions within 30 days of the index
exacerbation. We examined proportions and
Chi-square tests (for categorical variables) and
means, standard deviations, and t tests (for
continuous variables) of factors that might have
been related to health costs and outcomes and
receipt of Acthar prescriptions, including
patient age, gender, type of health insurance
plan, Deyo–Charlson Comorbidity Index
[18, 19], comorbidity categories, geographic
region, year of index relapse, and the number
of outpatient services, hospitalizations, and
medications filled in the 6 months prior to
index incident. Variables with P values of
\0.05 were considered significant confounders
in the subsequent adjusted regressions. The
authors were not blinded to whether subjects
received Acthar or PMP/IVIG when we
performed the analyses.
Next, we calculated unadjusted means,
medians, ranges, and standard deviations of
each healthcare utilization and cost among
patients who received Acthar prescriptions
compared to patients who received treatment
with PMPor IVIG.We calculated the proportions
of costs contributed by inpatient stays,
outpatient services, and medications. We also
calculated the absolute differences and the
p values for the differences between these
means for patients who received Acthar
prescriptions versus patients who received
treatment with PMP or IVIG. Outcomes related
to hospitalizations (length of stay, ICU
admissions, and readmissions) were only
calculated among patients with MS with at least
one hospitalization. Similarly, MS-related
emergency department visits were only
evaluated among patients with at least one
emergency department visit. If the index MS
exacerbation was identified from a
hospitalization to receive treatment with IVIG
or PMP, then that index inpatient stay was not
counted as a subsequent utilization.
Rehabilitation and long-term care services were
defined as inpatient and outpatient
rehabilitation facilities, skilled nursing
facilities, inpatient long-term care, nursing
facilities, and custodial care facilities. We then
performed generalized linear regressions for each
of the outcomes, adjusting for patient variables
that were significantly associated with receipt of
Acthar prescriptions. For outcomes with count
Table 1 Codes for treatment of multiple sclerosis relapses
Treatment name NDC, CPT, or HCPCS code
H.P. Acthar Gel (repository
corticotropin injection; Acthar)
NDC = 63004-77310-1, 63004-8710-01; HCPCS = J0800
IVMP HCPCS = J2920, J2930
IVIG CPT = 90284, 90283
HCPCS = J1559, J1561, J1562, J1566, J1568, J1569, J1572, J1599
PMP CPT = 36514, 36515
CPT Current Procedural Terminology, HCPCS Healthcare Common Procedure Coding System, IVIG intravenous
immunoglobulin, IVMP intravenous methylprednisolone, NDC National Drug Code, PMP plasmapheresis
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variables, such as thenumber of hospitalizations,
length of hospital stay, number of admissions to
an intensive care unit (ICU), number of
emergency department visits, number of
MS-related emergency department visits,
number of outpatient services, number of
rehabilitation services, the number of
prescription medications filled, and number of
all healthcare services combined we used
generalized linear regression with a log link and
specified the Poisson distribution to calculate
adjusted means and 95% confidence intervals
(CIs). For thebinaryoutcomeofwhether patients
were readmitted to thehospital within 30 days of
discharge, we used logistic regression to calculate
odds ratios (ORs) and 95%CIs. For total costs, we
used generalized linear regression with a log link
and specified the gamma distribution to
calculate adjusted means and 95% CIs. We also
calculated the absolute differences between the
adjusted means, as well as the 95% CI of these
differences.
SAS for Windows, version 9.3 (SAS Institute,
Inc., Cary, NC, USA) was used for all analyses.
Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, revised in 2013.
This study was exempt from review by the
University of Washington Institutional Review
Board (IRB) through self-determination.
RESULTS
For the 12-month analysis, a total of 6603
patients who met our enrollment criteria
experienced second relapses; of these, 461
(7%) received PMP, IVIG, or prescriptions for
Acthar. A total of 213 unique patients received
Acthar prescriptions within 30 days of the index
date, and 226 were treated with PMP or IVIG; 1
patient received both PMP and IVIG (Fig. 1). Six
patients who received Acthar prescriptions were
excluded, because they received treatment with
PMP or IVIG prior to receiving Acthar
prescriptions and 16 patients who received
Acthar prescriptions more than 30 days after
index exacerbation were deleted from these
analyses. In the 24-month analysis, 3836
patients who met our enrollment criteria
experienced second relapses and 238 (6%) of
these received PMP, IVIG, or prescriptions for
Acthar. A total of 96 patients received Acthar
prescriptions within 30 days of the index dates
and 132 were treated with PMP or IVIG (Fig. S1
in the supplementary material). In the
24-month analysis, no patients were excluded,
because they received treatment with PMP or
IVIG prior to receiving Acthar prescriptions, but
ten patients who received Acthar prescriptions
more than 30 days after their index
exacerbations were excluded.
Patients with 12-month outcomes who
received Acthar prescriptions were similar to
those who received PMP or IVIG in terms of age,
gender, type of health insurance plan, region,
and most comorbidities, but patients who
received Acthar prescriptions were less likely to
have a diagnosis of diabetes without
complications (7% vs. 14%; P = 0.03) and
patients whose index relapse occurred in later
years of the study were more likely to have
received Acthar prescriptions (Table 2).
Furthermore, patients who received Acthar
prescriptions had fewer outpatient services and
hospitalizations in the six months prior to the
index exacerbation, but filled more
prescriptions for all drugs in that time period
(Table 2). When we analyzed patients with MS
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with 24 months of continuous enrollment
(Table S1 in the supplementary material), we
found that patients who received Acthar
prescriptions were similar to those who
received PMP or IVIG in most respects, but
patients who received Acthar prescriptions were
more likely to have comorbid hemiplegia
(P = 0.01) and to have lived in the north
central or southern US (P = 0.01). Similar to
the 12-month outcomes cohort, patients who
Fig. 1 Study participant ﬂow for the 12-month analysis. PMP plasmapheresis, IVIG intravenous immunoglobulin, IVMP
intravenous methylprednisolone
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Table 2 Characteristics of patients with MS with 12-month outcomes receiving Acthar prescriptions compared to those






Age (years), mean ± SD (range) 43.6 ± 10 (18–63) 43.0 ± 11 (10–63) 0.57
Female 168 (79%) 184 (81%) 0.50
Type of health plan 0.83
Comprehensive 7 (3.5%) 6 (3%)
Exclusive/preferred provider organization 136 (67%) 150 (67%)
Health maintenance organization 28 (14%) 31 (14%)
Point of service 18 (8.9%) 25 (11%)
Consumer-directed/high-deductible 14 (6.9%) 11 (5%)
Missing 10 (4.6%) 3 (1%)
Charlson Comorbidity Index 0.19
0 131 (62%) 130 (58%)
1 42 (20%) 49 (22%)
2 24 (11%) 18 (8%)
3? 16 (7.5%) 29 (13%)
Comorbidity groups
Myocardial infarction 2 (0.9%) 1 (0.4%) 0.62
Congestive heart failure 2 (0.9%) 2 (0.9%) 1.0
Peripheral vascular disease 8 (3.7%) 6 (2.7%) 0.55
Cerebrovascular disease 18 (8.5%) 27 (12%) 0.23
Dementia 0 (0.0%) 0 (0.0%) NA
Chronic pulmonary disease 39 (18%) 36 (16%) 0.51
Rheumatoid diseases 12 (5.5%) 17 (8%) 0.38
Peptic ulcer disease 3 (1.4%) 5 (2.2%) 0.72
Chronic liver disease 1 (0.5%) 1 (0.4%) 1.0
Diabetes without complications 16 (7.3%) 31 (14%) 0.03
Diabetes with complications 2 (0.9%) 5 (2.2%) 0.45
Hemiplegia 13 (6.1%) 10 (4.4%) 0.43
Renal disease 3 (1.4%) 5 (2.2%) 0.73
Non-metastatic cancer 4 (1.9%) 13 (5.8%) 0.05
Sequelae of chronic liver disease 0 (0.0%) 1 (0.4%) 1.0
Metastatic cancer 1 (0.5%) 0 (0.0%) 0.49
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received Acthar prescriptions in the 24-month
cohort had fewer outpatient services and
hospitalizations but more medications in the
6 months prior to the index exacerbation. In
the cohort of patients with 12-month
outcomes, three patients received both Acthar
and IVIG within 30 days, and one patient
received both Acthar and PMP within 30 days.
In the cohort of patients with 24-month
outcomes, one patient received both Acthar
and IVIG within 30 days and no patients
received both Acthar and PMP within 30 days
of the index exacerbation.
When we examined unadjusted 12-month
outcomes (Table 3) among patients who
received Acthar prescriptions compared to
those who received PMP or IVIG, we found
that patients who received Acthar prescriptions
had, on average, 0.4 fewer hospitalizations (95%









AIDS 0 (0.0%) 0 (0.0%) NA
Geographic region
Northeast 47 (22%) 48 (22%) 0.10
North Central 44 (20%) 44 (20%)
South 90 (42%) 93 (43%)
West 28 (13%) 30 (14%)
Missing 4 (1.8%) 1 (0.4%)
Year of second MS exacerbation
2007 0 14 (6%) \0.0001
2008 2 (0.9%) 51 (23%)
2009 14 (6.4%) 55 (24%)
2010 36 (16%) 49 (22%)
2011 76 (36%) 36 (16%)
2012 85 (40%) 21 (9%)
Prior 6 months healthcare utilization, mean ± SD (range)
Outpatient services 8.6 ± 7.0 (0–45) 12 ± 8 (0–36) \0.0001
Hospitalizations 0.05 ± 0.3 (0–3) 0.3 ± 0.5 (0–3) \0.0001
Medications 11.7 ± 9.2 (0–60) 8.2 ± 8.8 (0–78) \0.0001
Values are given as n (%) unless otherwise stated
IVIG intravenous immunoglobulin, MS multiple sclerosis, PMP plasmapheresis, Rx prescription, SD standard deviation
a Three patients who received Acthar prescriptions also received IVIG within 30 days and 1 also received PMP within
30 days
b By deﬁnition, patients who received treatment with PMP or IVIG could not have received Acthar prescriptions
c Chi-square test used for categorical variables; t test used for continuous variables
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services (95% CI -23 to -11). Patients who
received Acthar prescriptions had 14 more
prescription medication fills (95% CI 8 to 20)
on average. We found that patients who
received Acthar prescriptions had, on average,
shorter lengths of stay in the hospital (3.3 days
less; 95% CI -0.2 to -6.5) and $15,300 lower
inpatient costs (95% CI -$24,000 to -$6500)
relative to patients who received PMP or IVIG.
Patients who received Acthar prescriptions also
had $54,100 lower outpatient costs (95% CI
-$80,000 to -$28,000), $74,900 (95% CI
$67,000 to $83,000) greater medication costs,
but similar average total costs relative to
patients who received PMP or IVIG ($5500
higher for Acthar patients; 95% CI -$22,000
to $34,000). Although the costs of medications
were increased in the group that received Acthar
prescriptions, these costs were offset by 93%
(among the cohort with 12 months of
follow-up) and 132% (among the cohort with
24 months of follow-up) by the relative decrease
in inpatient and outpatient costs among the
group that received Acthar prescriptions.
Following adjustment for significant
demographic variables, we found that patients
who received Acthar received 3.2 fewer
healthcare services overall on average (95% CI
-5.2 to -1.1), 0.2 fewer mean hospitalizations
(95%CI-0.3 to-0.1), shorter lengths ofhospital
stay (3.7 days less; 95%CI-4.8 to-1.1), 15 fewer
outpatient services (95% CI -20 to -10), and
similar total costs (Acthar total costs were $3000
lower; 95%CI-$21,000 to$15,000) compared to
patients who received PMP or IVIG (Table 4). In
addition, following adjustment, we found
patients who received Acthar prescriptions had,
on average, increased numbers of prescriptions
filled (six more prescriptions; 95% CI 4–7) over
the 12-month study period. Similar unadjusted
and adjusted results were also observed when we
examined patients who received Acthar
prescriptions compared to patients who
received PMP or IVIG with 24 months of
continuous enrollment except we did not
observe statistically significantly reduced
lengths of stay in the hospital (Tables S2 and S3
in the supplementary material).
Estimated proportions of adjusted costs,
categorized into medication, outpatient, and
hospitalization costs are shown in Fig. 2 and
Fig. S2 (in the supplementary material).
Medication costs comprised the greatest
proportion of the total costs in Acthar
prescription recipients in both the 12- and the
24-month cohorts. For PMP/IVIG recipients,
outpatient costs comprised the greatest
proportion of the total costs in both cohorts.
DISCUSSION
Compared to patients who received PMP or
IVIG for MS exacerbations, adjusted analyses
showed that patients who received Acthar
prescriptions tended to utilize fewer inpatient
and outpatient healthcare services. While
patients who received Acthar prescriptions
received more prescription medications of any
type and had higher proportions of medication
costs compared to patients who received PMP or
IVIG, total adjusted costs were similar between
the two groups. These results remained when
we examined patients who were enrolled in our
cohort for 24 months continuously.
The mechanism of action of Acthar
continues to be explored as current research
suggests Acthar may have anti-inflammatory
and immunomodulatory properties [15, 20].
Some research has shown that Acthar may
benefit patients who do not respond to or
tolerate other treatments [21]. While large or
long-term trials assessing the use of Acthar for
treating MS relapses have not been conducted,
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the current evidence shows it may have an
important role by, for example, minimizing
inpatient admissions, which have been
associated with MS-related costs [22].
This studyhadseveral limitations. First, because
we defined exposure to Acthar using outpatient
prescription claims data, it is possible that some
patients were subject to misclassification, because
they did not actually inject the medication.
Furthermore, because this was an observational
study and not a randomized controlled trial, we
cannot be certain that the differences we observed
between patients who did and did not receive
Acthar prescriptions were not affected by
confounding factors. We corrected for this by
adjusting our models for potentially confounding
variables, but unmeasured factors might have
played a role in the associations that we reported.
Table 4 Adjusted 12-month outcomes among patients who received Acthar prescriptions compared to patients who
received PMP or IVIG
12-month outcome Adjusted mean
(95% CI) for patients
receiving Acthara
Adjusted mean







Number of all healthcare services 73 (71, 74) 76 (74, 77) -3.2 (-5.2, -1.1) 0.003
Number of hospitalizations 0.2 (0.1, 0.3) 0.4 (0.3, 0.5) -0.2 (-0.3, -0.1) 0.01
Length of stay (days)b 3.0 (1.9, 4.7) 5.7 (4.2, 8.0) -3.7 (-4.8, -1.1) 0.01
# of Admissions to ICUb 0.05 (0.01. 0.37) 0.09 (0.03, 0.23) -0.4 (-0.08, 0.40) 0.66
Number of ER visits 0.4 (0.3, 0.5) 0.5 (0.4, 0.7) -0.1 (-0.3, 0.04) 0.12
Number of MS-related ER visitsc 0.6 (0.5, 1.0) 0.8 (0.6, 1.2) -0.2 (-0.4, 0.3) 0.36
Number of outpatient services 29 (26, 33) 43 (39, 46) -15 (-20, -10) \0.0001
Number of rehab and long-term
care facilities services
0.04 (0.02, 0.07) 0.23 (0.17, 0.32) -0.19 (-0.26, -0.12) \0.0001
Number of prescriptions 36 (35, 38) 30 (29, 31) 6 (4, 7) \0.0001







12-month outcome Adjusted mean
(95% CI) for patients
receiving Acthara








0.3 (0.02, 0.6) 0.2 (0.02, 0.4) 1.4 (0.3, 7.7) 0.68
CI conﬁdence interval, ER emergency room, ICU intensive care unit, IVIG intravenous immunoglobulin, PMP
plasmapheresis, MS multiple sclerosis
a Adjusted for the number of relapses prior to index date, days between exacerbations, comorbid diabetes without
complications, year of index exacerbation, and number of outpatient services, hospitalizations, and medications in the
6 months prior to the index exacerbation
b Length of stay, admissions to ICU, and readmissions within 30 days calculated only among patients with at least 1
hospitalization
c MS-related ER visits only calculated among patients with at least 1 ER visit
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In addition, althoughwemadedirect comparisons
between treatment with Acthar versus treatment
with IVIG or PMP, the determination of the
efficacies of IVIG and PMP to treat MS relapses is
ongoing [14, 17, 23]. Becausewewere interested in
outcomes thatoccurredover the12and24months
the subsequent MS exacerbation, we excluded
patients who were not enrolled in their health
plans for one or two years after the index event, so
our population was stable by definition, and our
results are likely not generalizable to more
transient populations. In addition, since we
included only patients who experienced multiple
relapsesandwhoreceivedtreatmentsbesides IVMP
for their subsequent relapses, our sample size was
fairly small and our results are not generalizable to
the broaderMS population that responds to IVMP.
In addition, although we closely followed a
pre-determined analysis plan, we were not
blinded to whether subjects received Acthar or
PMP/IVIG when we performed the analyses. We
also did not have information on procedures or
health utilizations for which patients paid
out-of-pocket rather than filing claims through
their insurance companies, and our cost estimates
might, therefore, be conservative. Furthermore,
the population of patients in the MarketScan
databases is not randomly sampled and some
populations, such as patients insured by small
employers or patients who do not have insurance
(or do not have spouses with insurance) were not
represented in this study population. Therefore,
these results may not be generalizable across all
patients with MS in the US. Finally, as with any
claims-based study, our data may have included
coding errors with diagnoses or procedures.
CONCLUSIONS
Using the medical and pharmacy claims from
Truven Health Analytics MarketScan Databases,
we assessed resource utilization, outcomes, and
Fig. 2 Adjusted (for number of relapses prior to index date,
days between exacerbations, comorbid diabetes without
complications, year of index exacerbation, and number of
outpatient services, hospitalizations, and medications in the
6 months prior to the index exacerbation) proportions of
12-month cost components among patients with multiple
sclerosis who were prescribed Acthar compared to those
who received PMP or IVIG. PMP plasmapheresis, IVIG
intravenous immunoglobulin
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costs in patients with MS experiencing multiple
relapses. Compared to patients using PMP or IVIG,
patients receiving Acthar prescriptions had fewer
outpatient services and hospitalizations, and
similar overall costs. Although further studies are
necessary to confirm these findings and decisions
about treatment forMS relapsesmust be tailored to
specific patients’ clinical factors, Acthar may be a
useful treatment option for patients with MS
experiencing relapses who are unable to be
treated with IVMP. Further research should be
conducted to determine its cost-effectiveness in
MS relapse treatment compared to other agents.
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